Meeting
2023 ASCO Annual Meeting
Prospective prevalence estimation of BRCA1, BRCA2, and other germline mutations associated with hereditary pancreatic cancer (HPC) using a comprehensive gene panel in an unselected cohort of Mexican patients with pancreatic ductal adenocarcinoma (PDAC).
Authors
Vanessa Rosas Camargo
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Vanessa Rosas Camargo , Jazmin Arteaga , Javier Melchor Ruan , Salvador Escorza , Alberto Cedro-Tanda , Silvia Vidal , Lucero Itzel Torres Valdiviezo , Miriam Heidi Cisneros Cordero , Cesar Arce Sandoval , Mónica Isabel Meneses Medina , Marytere Herrera , Fidel David David Huitzil Melendez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10609)
DOI
10.1200/JCO.2023.41.16_suppl.10609
Abstract #
10609
Poster Bd #
242
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Tumor sequencing with germline genetic testing: Identification of patients with hereditary cancer and precision treatment eligibility.
First Author: Scott T. Michalski
Poster
2021 ASCO Annual Meeting
Identification of potential germline (GL) variants by routine clinical comprehensive genomic profiling (CGP) and confirmatory GL testing in 24 tumor types.
First Author: Kristen Hanson
Poster
2020 Genitourinary Cancers Symposium
Prevalence of pathogenic germline risk variants (PVs) in 1829 renal cell carcinoma (RCC) patients (pts).
First Author: Sarah Abou Alaiwi
Poster
2017 Genitourinary Cancers Symposium
Inherited pathologic mutations and family history in patients with prostate cancer.
First Author: Shuwen Lin